These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

603 related articles for article (PubMed ID: 27023227)

  • 1. Cytokine Profile in Patients with Progressive Multiple Sclerosis and Its Association with Disease Progression and Disability.
    Kallaur AP; Oliveira SR; Simão ANC; Alfieri DF; Flauzino T; Lopes J; de Carvalho Jennings Pereira WL; de Meleck Proença C; Borelli SD; Kaimen-Maciel DR; Maes M; Reiche EMV
    Mol Neurobiol; 2017 May; 54(4):2950-2960. PubMed ID: 27023227
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytokine profile in relapsing‑remitting multiple sclerosis patients and the association between progression and activity of the disease.
    Kallaur AP; Oliveira SR; Colado Simão AN; Delicato de Almeida ER; Kaminami Morimoto H; Lopes J; de Carvalho Jennings Pereira WL; Marques Andrade R; Muliterno Pelegrino L; Donizete Borelli S; Kaimen-Maciel DR; Reiche EM
    Mol Med Rep; 2013 Mar; 7(3):1010-20. PubMed ID: 23292766
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of endogenous antiradical protective system in multiple sclerosis.
    Davitashvili D; Beridze M; Shakarishvili R; Kiziria M; Sanikidze T
    Georgian Med News; 2012 Apr; (205):11-9. PubMed ID: 22665726
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor necrosis factor-alfa and interleukin-4 in cerbrospinal fluid and plasma in different clinical forms of multiple sclerosis.
    Obradović D; Kataranovski M; Dincić E; Obradović S; Colić M
    Vojnosanit Pregl; 2012 Feb; 69(2):151-6. PubMed ID: 22500369
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sex differences in in vitro pro-inflammatory cytokine production from peripheral blood of multiple sclerosis patients.
    Nguyen LT; Ramanathan M; Weinstock-Guttman B; Baier M; Brownscheidle C; Jacobs LD
    J Neurol Sci; 2003 May; 209(1-2):93-9. PubMed ID: 12686409
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical and laboratory study of pro-inflammatory and antiinflammatory cytokines in women with multiple sclerosis.
    Trenova AG; Manova MG; Kostadinova II; Murdjeva MA; Hristova DR; Vasileva TV; Zahariev ZI
    Folia Med (Plovdiv); 2011; 53(2):29-35. PubMed ID: 21797104
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cytokines and disability in interferon-β-1b treated and untreated women with multiple sclerosis.
    Trenova AG; Slavov GS; Manova MG; Kostadinova II
    Arch Med Res; 2014 Aug; 45(6):495-500. PubMed ID: 25130430
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A clinical and laboratory study evaluating the profile of cytokine levels in relapsing remitting and secondary progressive multiple sclerosis.
    Pasquali L; Lucchesi C; Pecori C; Metelli MR; Pellegrini S; Iudice A; Bonuccelli U
    J Neuroimmunol; 2015 Jan; 278():53-9. PubMed ID: 25595252
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interferon-beta regulates cytokines and BDNF: greater effect in relapsing than in progressive multiple sclerosis.
    Hamamcioglu K; Reder AT
    Mult Scler; 2007 May; 13(4):459-70. PubMed ID: 17463069
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dysregulation of the IL-23/IL-17 axis and myeloid factors in secondary progressive MS.
    Huber AK; Wang L; Han P; Zhang X; Ekholm S; Srinivasan A; Irani DN; Segal BM
    Neurology; 2014 Oct; 83(17):1500-7. PubMed ID: 25253754
    [TBL] [Abstract][Full Text] [Related]  

  • 11. T2 lesions and rate of progression of disability in multiple sclerosis.
    Mostert JP; Koch MW; Steen C; Heersema DJ; De Groot JC; De Keyser J
    Eur J Neurol; 2010 Dec; 17(12):1471-5. PubMed ID: 20500805
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Profiling of Canonical and Non-Traditional Cytokine Levels in Interferon-β-Treated Relapsing-Remitting-Multiple Sclerosis Patients.
    D'Angelo C; Reale M; Costantini E; Di Nicola M; Porfilio I; de Andrés C; Fernández-Paredes L; Sánchez-Ramón S; Pasquali L
    Front Immunol; 2018; 9():1240. PubMed ID: 29915590
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytokine profile, Foxp3 and nuclear factor-kB ligand levels in multiple sclerosis subtypes.
    Alatab S; Maghbooli Z; Hossein-Nezhad A; Khosrofar M; Mokhtari F
    Minerva Med; 2011 Dec; 102(6):461-8. PubMed ID: 22193377
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intrathecal activation of the IL-17/IL-8 axis in opticospinal multiple sclerosis.
    Ishizu T; Osoegawa M; Mei FJ; Kikuchi H; Tanaka M; Takakura Y; Minohara M; Murai H; Mihara F; Taniwaki T; Kira J
    Brain; 2005 May; 128(Pt 5):988-1002. PubMed ID: 15743872
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic, Immune-Inflammatory, and Oxidative Stress Biomarkers as Predictors for Disability and Disease Progression in Multiple Sclerosis.
    Kallaur AP; Reiche EMV; Oliveira SR; Simão ANC; Pereira WLCJ; Alfieri DF; Flauzino T; Proença CM; Lozovoy MAB; Kaimen-Maciel DR; Maes M
    Mol Neurobiol; 2017 Jan; 54(1):31-44. PubMed ID: 26732588
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum Levels of Biomarkers of Immune Activation and Associations With Neurological Impairment in Relapsing-Remitting Multiple Sclerosis Patients During Remission.
    Witkowska AM; Socha K; Kochanowicz J; Karpińska E; Jakoniuk M; Zujko ME; Wilkiel M; Borawska MH; Mariak Z
    Biol Res Nurs; 2016 Jan; 18(1):113-9. PubMed ID: 25911236
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized study of antibodies to IFN-gamma and TNF-alpha in secondary progressive multiple sclerosis.
    Skurkovich S; Boiko A; Beliaeva I; Buglak A; Alekseeva T; Smirnova N; Kulakova O; Tchechonin V; Gurova O; Deomina T; Favorova OO; Skurkovic B; Gusev E
    Mult Scler; 2001 Oct; 7(5):277-84. PubMed ID: 11724442
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Circulating levels of interleukin-17A, tumor necrosis factor-alpha, interleukin-18, interleukin-10, and cognitive performance of patients with relapsing-remitting multiple sclerosis.
    Trenova AG; Slavov GS; Draganova-Filipova MN; Mateva NG; Manova MG; Miteva LD; Stanilova SA
    Neurol Res; 2018 Mar; 40(3):153-159. PubMed ID: 29297273
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relationship between cerebrospinal fluid biomarkers of inflammation and tissue damage in primary progressive multiple sclerosis.
    Talbot J; Højsgaard Chow H; Mahler M; Buhelt S; Holm Hansen R; Lundell H; Vinther-Jensen T; Hellem MNN; Nielsen JE; Siebner HR; von Essen MR; Sellebjerg F
    Mult Scler Relat Disord; 2022 Dec; 68():104209. PubMed ID: 36257152
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased plasma 8,12-iso-iPF2alpha- VI levels in relapsing multiple sclerosis patients are not predictive of disease progression.
    Teunissen CE; Sombekke M; van Winsen L; Killestein J; Barkhof F; Polman CH; Dijkstra CD; Blankenstein MA; Pratico D
    Mult Scler; 2012 Aug; 18(8):1092-8. PubMed ID: 22695538
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.